J R Thistlethwaite

Emory University, Atlanta, Georgia, United States

Are you J R Thistlethwaite?

Claim your profile

Publications (133)448.98 Total impact

  • D C Cronin · E M Alonso · J B Piper · KA Newell · D S Bruce · E S Woodle · P F Whitington · J R Thistlethwaite · J M Millis ·

    Transplantation Proceedings 01/2004; 29(1-2):419-20. DOI:10.1016/S0041-1345(96)00160-1 · 0.98 Impact Factor
  • Source
    Z Guo · J Wang · L Meng · Q Wu · O Kim · J Hart · G He · P Zhou · J R Thistlethwaite · M L Alegre · Y X Fu · K A Newell ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Blocking the CD28/B7 and/or CD154/CD40 costimulatory pathways promotes long-term allograft survival in many transplant models where CD4(+) T cells are necessary for rejection. When CD8(+) T cells are sufficient to mediate rejection, these approaches fail, resulting in costimulation blockade-resistant rejection. To address this problem we examined the role of lymphotoxin-related molecules in CD8(+) T cell-mediated rejection of murine intestinal allografts. Targeting membrane lymphotoxin by means of a fusion protein, mAb, or genetic mutation inhibited rejection of intestinal allografts by CD8(+) T cells. This effect was associated with decreased monokine induced by IFN-gamma (Mig) and secondary lymphoid chemokine (SLC) gene expression within allografts and spleens respectively. Blocking membrane lymphotoxin did not inhibit rejection mediated by CD4(+) T cells. Combining disruption of membrane lymphotoxin and treatment with CTLA4-Ig inhibited rejection in wild-type mice. These data demonstrate that membrane lymphotoxin is an important regulatory molecule for CD8(+) T cells mediating rejection and suggest a strategy to avoid costimulation blockade-resistant rejection.
    The Journal of Immunology 12/2001; 167(9):4796-800. DOI:10.4049/jimmunol.167.9.4796 · 4.92 Impact Factor
  • G L Szot · P Zhou · I Rulifson · J Wang · Z Guo · O Kim · K A Newel · J R Thistlethwaite · J A Bluestone · M L Alegre ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Although CD28 blockade results in long-term cardiac allograft survival in wildtype mice, CD28-deficient mice effectively reject heart allografts. This study compared the mechanisms of allogeneic responses in wildtype and CD28-deficient mice. Adoptive transfer of purified CD28-deficient T cells into transplanted nude mice resulted in graft rejection. However, this model demonstrated that the allogeneic T cell function was severely impaired when compared with wildtype T cells, despite similar survival kinetics. Cardiac allograft rejection depended on both CD4+ and CD8+ T cell subsets in CD28-deficient mice, whereas only CD4+ T cells were necessary in wildtype recipients. These results suggested that CD8+ T cells were more important in CD28-deficient than wildtype mice. In addition to the CD8+ T cell requirement, allograft rejection in CD28-deficient mice was dependent on a sustained presence of CD4+ T cells, whereas it only required the initial presence of CD4+ T cells in wildtype mice. Taken together, these data suggest that CD4+ T cells from CD28-deficient mice have impaired responses to alloantigen in vivo, thus requiring long-lasting cooperation with CD8+ T cell responses to facilitate graft rejection. These results may help to explain the failure to promote graft tolerance in some preclinical and clinical settings.
    American Journal of Transplantation 06/2001; 1(1):38-46. · 5.68 Impact Factor
  • S.M. Meehan · P Domer · M Josephson · M Donoghue · A Sadhu · L.T. Ho · A.J. Aronson · J.R. Thistlethwaite · M Haas ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Plasmacytic infiltrates in renal allograft biopsies are uncommon and morphologically distinctive lesions that may represent variants of acute rejection. This study sought significant clinical and pathologic determinants that might have influenced development of these lesions and assessed their prognostic significance. Renal allograft biopsies (n = 19), from 19 patients, with tubulointerstitial inflammatory infiltrates containing abundant plasma cells, composing 32 +/- 8% of the infiltrating mononuclear cells, were classified using Banff '97 criteria. Clonality of the infiltrates was determined by immunoperoxidase staining for kappa and lambda light chains and polymerase chain reaction for immunoglobulin heavy-chain gene rearrangements, using V(H) gene framework 3 and JH consensus primers. In situ hybridization for Epstein-Barr virus encoded RNA (EBER) was performed in 17 cases. The clinical features, histology, and outcome of these cases were compared with kidney allograft biopsies (n = 17) matched for time posttransplantation and type of rejection by Banff '97 criteria, with few plasma cells (7 +/- 5%). Sixteen of 19 biopsies (84%) with plasmacytic infiltrates had EBER-negative (in 14 cases tested) polyclonal plasma cell infiltrates that were classifiable as acute rejection (types 1A [4], 1B [10], and 2A [2]). These biopsies were obtained between 10 and 112 months posttransplantation. Graft loss from acute and/or chronic rejection was 50% at 1 year and 63% at 3 years, and the median time to graft failure was 4.5 months after biopsy. There was no significant difference in overall survival or time to graft failure compared with the controls. Three of 19 biopsies (16%) had EBER-negative polyclonal plasmacytic hyperplasia, mixed monoclonal and polyclonal polymorphous B cell hyperplasia, and monoclonal plasmacytoma-like posttransplantation lymphoproliferative disease (PTLD) and were obtained at 17 months, 12 weeks, and 7 years after transplantation, respectively. Graft nephrectomies were performed at 1, 19, and 5 months after biopsy, respectively. Plasmacytic infiltrates in renal allografts comprise a spectrum of lesions from acute rejection to PTLD, with a generally poor prognosis for long-term graft survival.
    Human Pathlogy 03/2001; 32(2):205-15. DOI:10.1053/hupa.2001.21574 · 2.77 Impact Factor
  • P Zhou · G Szot · Z Guo · O Kim · G He · J Wang · M Grusby · K Newell · J Thistlethwaite · J Bluestone · M Alegre ·

    Transplantation Proceedings 02/2001; 33(1):214-216. DOI:10.1016/S0041-1345(00)01979-5 · 0.98 Impact Factor
  • M Alegre · F Fallarino · P Zhou · K Frauwirth · J Thistlethwaite · K Newell · T Gajewski · J Bluestone ·

    Transplantation Proceedings 02/2001; 33(1-2):209-11. DOI:10.1016/S0041-1345(00)01977-1 · 0.98 Impact Factor
  • P Zhou · G Szot · Z Guo · O Kim · G He · J Wang · M Grusby · K Newell · J Thistlethwaite · J Bluestone · M Alegre ·

    Transplantation Proceedings 01/2001; 33(1-2):214-6. · 0.98 Impact Factor
  • P Zhou · G L Szot · Z Guo · O Kim · G He · J Wang · M J Grusby · K A Newell · J R Thistlethwaite · J A Bluestone · M L Alegre ·
    [Show abstract] [Hide abstract]
    ABSTRACT: STAT4(-/-) mice have impaired type 1 T cell differentiation, whereas STAT6(-/-) mice fail to generate type 2 responses. The role of type 1 and type 2 T cell differentiation in acute cardiac allograft rejection and in the induction of tolerance was examined in wild-type, STAT4(-/-), and STAT6(-/-) recipients. All recipients rejected the grafts promptly. Analysis of in situ cytokine gene expression in the allografts confirmed decreased levels of IFN-gamma in STAT4(-/-) recipients and undetectable levels of IL-4 and IL-5 in STAT6(-/-) mice. Blockade of the CD28/B7 costimulatory pathway prolonged cardiac graft survival for >100 days in 100% of wild-type and STAT4(-/-) mice. However, 14% of CTLA4-Ig-treated STAT6(-/-) mice rejected their grafts between 20 and 100 days. Moreover, of those animals followed past 100 days, 60% of the STAT6(-/-) mice rejected their grafts. Splenocytes harvested on day 145 posttransplant from CTLA4-Ig-treated rejecting STAT6(-/-) recipients were transfused into syngeneic SCID mice transplanted with donor or third party cardiac allografts. Both donor and third party grafts were rejected, indicating that the initial graft loss may be due to an immunological rejection. In contrast, when splenocytes from CTLA4-Ig-treated wild-type or nonrejecting STAT6(-/-) mice were transferred into SCID recipients, donor allografts were accepted, but third party hearts were rejected. Thus, long-term prolongation of cardiac allograft survival by CTLA4-Ig is STAT4-independent but, at least in part, STAT6-dependent. These data suggest that the balance of type 1 and type 2 T lymphocyte differentiation is not critical for acute rejection but influences the robust tolerance induced by CD28/B7 blockade in this model.
    The Journal of Immunology 11/2000; 165(10):5580-7. DOI:10.4049/jimmunol.165.10.5580 · 4.92 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Preexisting renal dysfunction has been reported to significantly increase the morbidity and mortality associated with orthotopic liver transplantation (OLT). OLT alone has been recommended for adults and children with end-stage liver disease and reversible causes of renal failure (i.e., hepatorenal syndrome), whereas combined liver and kidney transplantation (LKT) has been shown to be an effective treatment for adults with combined end-stage liver and kidney disease. The purpose of this study was to examine the role of LKT in children. Between October of 1984 and 1997, 385 children less than 18 years of age underwent OLT at the University of Chicago. During this same time period 12 patients underwent LKT. Data were gathered by retrospective review of the patients medical records and by interviews conducted with the patients' families. Actuarial patient survival was comparable for children who underwent OLT alone and LKT (69% versus 67% at 5 years). All allograft losses in the LKT group were the result of patient death and occurred within the first 90 postoperative days. Factors associated with decreased patient survival included severity of illness as reflected by United Network of Organ Sharing status and LKT after failed OLT or cadaveric renal transplant. In children with concomitant endstage liver and kidney disease, LKT can be considered an effective therapeutic option in selected patients. Long-term patient survival in patients undergoing LKT is comparable to that of patients with normal renal function undergoing OLT alone.
    Transplantation 08/2000; 70(1):100-5. DOI:10.1097/00007890-199810270-00230 · 3.83 Impact Factor

  • Liver Transplantation 05/2000; 6(3). DOI:10.1016/S1527-6465(05)80049-8 · 4.24 Impact Factor
  • Source
    E S Woodle · D Xu · R A Zivin · J Auger · J Charette · R O'Laughlin · D Peace · L K Jollife · T Haverty · J A Bluestone · J R Thistlethwaite ·
    [Show abstract] [Hide abstract]
    ABSTRACT: HuOKT3gamma1(Ala-Ala) is a genetically-engineered derivative of the parental murine OKT3 monoclonal antibody, in which the six complementarity-determining regions have been grafted within a human IgG1 mAb, and whose C(H)2 region has been altered by site-directed mutagenesis to alter FcR-binding activity, thereby eliminating T cell activation properties. This report describes the results of a phase I trial of huOKT3gamma1(Ala-Ala) treatment of acute renal allograft rejection. Acute renal allograft rejection in kidney and kidney-pancreas transplant recipients was treated with huOKT3gamma1(Ala-Ala). huOKT3gamma1(Ala-Ala) dosing consisted of daily 5- or 10-mg doses adjusted initially to achieve target levels of 1000 ng/ml. A total of seven patients, five kidney transplant and two kidney-pancreas transplant recipients, were treated with the monoclonal antibody for first rejection episodes. Corticosteroids (500 mg i.v. Solumedrol) were given 2 hr before the first huOKT3gamma1(Ala-Ala) dose only. Banff classification of treated rejections were the following: grade I, 1 patient, grade IIA, 1 patient, grade IIB, 4 patients, and grade III, 1 patient. Median time from transplant to rejection was 15 days, and median follow up 12 months (range 10-17 months). HuOKT3gamma1(Ala-Ala) therapy was given for 10.1+/-2.5 days, and mean total dose was 76+/-27 mg. Rejection was reversed in five of seven patients, and recurrent rejection was observed in one patient. Serum creatinine values peaked on day 1 of huOKT3gamma1(Ala-Ala) therapy, and thereafter demonstrated a progressive decline. Rejection reversal (return of creatinine to baseline) occurred at a median of 4 days and a mean of 4.1+/-2 days. Renal allograft biopsies obtained during huOKT3gamma1(Ala-Ala) therapy provided evidence of rapid rejection reversal. Patient and graft survival were both 100%. First dose reactions were minimal, and anti-OKT3 antibodies were not detected. Elevations in serum IL-10, but not IL-2 levels were observed after the first huOKT3gamma1(Ala-Ala) dose. Marked reductions in circulating CD2+, CD4+, and CD8+ T cells were observed after the first huOKT3gamma1(Ala-Ala) dose, followed by a slow progressive return of cell counts toward pretreatment values. Pharmacokinetic analysis revealed a half-life of 142+/-32 hr. HuOKT3gamma1(Ala-Ala) possesses the ability to reverse vigorous rejection episodes in kidney and kidney-pancreas transplant recipients, and in comparison to murine OKT3, possesses minimal first dose reactions and does not seem to induce antibodies that bind the OKT3 idiotype. These results support the conduct of additional clinical trials with the huOKT3gamma1(Ala-Ala) antibody.
    Transplantation 10/1999; 68(5):608-16. · 3.83 Impact Factor
  • Source
    KA Newell · G He · Z Guo · O Kim · G L Szot · I Rulifson · P Zhou · J Hart · J R Thistlethwaite · J A Bluestone ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The effect of blocking the CD28/B7 costimulatory pathway on intestinal allograft rejection was examined in mice. Murine CTLA4Ig failed to prevent the rejection of allografts transplanted into wild-type or CD4 knockout (KO) mice but did inhibit allograft rejection by CD8 KO recipients. This effect was associated with decreased intragraft mRNA for IFN-gamma and TNF-alpha and increased mRNA for IL-4 and IL-5. This altered pattern of cytokine production was not observed in allografts from murine CTLA4Ig-treated CD4 KO mice. These data demonstrate that blockade of the CD28/B7 pathway has different effects on intestinal allograft rejection mediated by CD4+ and CD8+ T cells and suggest that these T cell subsets have different costimulatory requirements in vivo. The results also suggest that the inhibition of CD4+ T cell-mediated allograft rejection by CTLA4Ig may be related to down-regulation of Th1 cytokines and/or up-regulation of Th2 cytokines.
    The Journal of Immunology 10/1999; 163(5):2358-62. · 4.92 Impact Factor
  • Source
    S M Meehan · C T Siegel · A J Aronson · S M Bartosh · J R Thistlethwaite · E S Woodle · M Haas ·
    [Show abstract] [Hide abstract]
    ABSTRACT: The relationship of borderline infiltrates to acute rejection by Banff criteria in renal allografts of patients receiving only maintenance immunosuppression is not clear. Renal allograft biopsies with borderline lesions that were not treated with additional anti-rejection therapy were retrospectively studied. Sixty-five such biopsies were identified from 50 patients, and their outcome was determined by serum creatinine and/or histologic findings in subsequent biopsies, up to 40 d after the initial biopsy. In addition to the borderline infiltrates, there was evidence of acute cyclosporine or tacrolimus toxicity (58%), acute tubular necrosis (12%), and urinary obstruction (12%). Forty-day follow-up after 30 (46%) biopsies revealed serum creatinine < 110% of baseline, and repeat biopsies were not indicated. In 17 (26%), the serum creatinine initially decreased, then increased, and follow-up biopsies showed acute rejection in nine. In 18 (28%), the creatinine remained elevated and follow-up biopsies revealed acute rejection in nine. The untreated borderline infiltrates were thus nonprogressive after 47 biopsies (72%) and progressed to histologic acute rejection after 18 (28%). When there was increasing or persistently elevated creatinine after the initial biopsy, 51% of cases (18 of 35) progressed to acute rejection. Infiltrates that progressed to rejection had more frequent glomerulitis (7 of 18 versus 3 of 47, P = 0.003) and Banff acute score indices (i+t+v+g) >2 (16 of 18 versus 29 of 47, P = 0.03). A majority (72%) of borderline infiltrates not given additional anti-rejection therapy did not progress to acute rejection over 40 d of follow-up, suggesting that conservative management of these lesions, at least in the short term, may be more appropriate than routine treatment as acute rejection.
    Journal of the American Society of Nephrology 09/1999; 10(8):1806-14. · 9.34 Impact Factor
  • Source
    B R Theriault · J R Thistlethwaite · M G Levisetti · C L Wardrip · G Szot · D S Bruce · H Rilo · X Li · G S Gray · JA Bluestone · PA Padrid ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Insulin-dependent diabetes mellitus (IDDM) is the second most prevalent chronic illness of children. Investigation of the treatment of IDDM is hindered by the lack of a reproducible and easily maintained non-human primate model of this disorder. We induced IDDM in 11 juvenile cynomolgus monkeys after a single (150 mg/kg) intravenous injection of streptozotocin (STZ). All diabetic monkeys were treated with insulin twice daily, based on a sliding scale. Subcutaneous vascular access ports were surgically placed in each monkey to facilitate serial blood sampling and drug administration. Allogeneic pancreatic islet cells from unrelated donors were subsequently transplanted into the mesenteric circulation of all STZ-treated monkeys. Mild, transient nausea and vomiting occurred in all animals after STZ injection; however, no additional signs of toxicity occurred. Within 36 hr, all monkeys required twice daily administration of exogenous insulin to maintain a non-ketotic state. Serum C-peptide levels decreased from >1.2 ng/ml before STZ, to between 0.0 and 0.9 ng/ml after STZ, confirming islet cell destruction. Animals were maintained in an insulin-dependent state for up to 147 days without any observable clinical complications. Subcutaneous vascular access port patency was maintained up to 136 days with a single incidence of local infection. Islet cell transplantation resulted in normoglycemia within 24 hr. Serum C-peptide levels increased (range: 2-8 ng/ml) for 6 - 8 days in immune competent animals, and for 39-98 days after transplant in immunosuppressed monkeys. IDDM can be consistently induced and safely treated in juvenile cynomolgus monkeys. Chronic vascular access can be maintained with minimal supervision and complications. This model is appropriate for studies investigating potential treatments for IDDM including islet cell transplantation.
    Transplantation 08/1999; 68(3):331-7. · 3.83 Impact Factor

  • Transplantation 05/1999; 67(9). DOI:10.1097/00007890-199905150-00216 · 3.83 Impact Factor
  • HLR Rilo · NF Chen · AR Rotramel · JS Fisher · JR Thistlethwaite ·

    Transplantation 05/1999; 67(9):S628-S628. · 3.83 Impact Factor
  • Z Guo · G He · O S Kim · J Hart · J R Thistlethwaite · KA Newell ·

    Transplantation 05/1999; 67(9). DOI:10.1097/00007890-199905150-00267 · 3.83 Impact Factor
  • J F Buell · L Brady · D Cronin · P Boone · C Siegel · C Jackson · A Kopelan · J Fischer · A Swanson · J R Thistlethwaite · J M Millis ·

    Transplantation 04/1999; 67(7). DOI:10.1097/00007890-199904150-00502 · 3.83 Impact Factor
  • KA Newell · G He · Z Guo · O Kim · J Hart · M Collins · J R Thistlethwaite · JA Bluestone ·

    Transplantation 04/1999; 67(7). DOI:10.1097/00007890-199904150-00181 · 3.83 Impact Factor
  • C Siegel · J Mead · J Buell · A Yoshida · K. Newell · E S Woodle · J R Thistlethwaite · D Bruce ·

    Transplantation 04/1999; 67(7):S223. DOI:10.1097/00007890-199904150-00890 · 3.83 Impact Factor

Publication Stats

4k Citations
448.98 Total Impact Points


  • 2001
    • Emory University
      • Department of Surgery
      Atlanta, Georgia, United States
  • 1999
    • Harvard University
      Cambridge, Massachusetts, United States
  • 1987-1998
    • University of Chicago
      • • Department of Surgery
      • • Department of Medicine
      Chicago, Illinois, United States
  • 1995
    • University of Illinois at Chicago
      • Division of Transplantation
      Chicago, IL, United States
  • 1988-1995
    • The University of Chicago Medical Center
      • • Section of Transplantation
      • • Department of Surgery
      Chicago, Illinois, United States